Quartz5h agobearish
Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2506last 7d
477● bullish (7d)
255● bearish (7d)
197publishers
Proactive8d agobearish
Dow set to extend gains as AI spending caution drags on NasdaqWall Street is heading for another mixed session on Tuesday, with blue-chip gains offset by concerns about AI spending and Chinese competition weighing on some technology stocks. Dow Jones futures were up 317 points, or 0.6%, but the Nasdaq has been called 1% lower, with S&P 500 futures...
Investor's Business Daily19d agobearish
Stock Market Today: Dow Slides As Netflix Plunges On Earnings; SpaceX Slides After Canceled Flight (Live Coverage)Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.
Simply Wall St.28d agobearish
Amgen (AMGN) Recalls Put Its Valuation Story Back In FocusAmgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...
Simply Wall St.28d agobearish
Did Enbrel’s Price Cap Reprieve and New Recalls Just Rebalance Amgen’s (AMGN) Risk‑Reward Profile?In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, while the company also initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the United States over foreign substances and CGMP deviations. This mix of regulatory relief on Enbrel’s pricing and ongoing quality-related recalls raises important questions about how investors weigh pricing power against...
Simply Wall St.29d agobearish
Amgen (AMGN) Recalls Sensipar And Corlanor In Broad US Quality SweepAmgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls involve multiple lots, dosage strengths, and large product quantities distributed nationwide. Regulators cited current good manufacturing practice (CGMP) deviations and contamination concerns affecting certain products. The pattern of recurring recalls extends beyond a single isolated lot or event. For investors following Amgen, ticker NasdaqGS:AMGN, the scale and...
Proactive44d agobearish
Nasdaq tipped to rise after long weekend of Iran talks progress, hawkish Fed still loomsUS futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...
Zacks55d agobearish
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to NoteIn the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Barchart65d agobearish
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.
